SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-20-111774
Filing Date
2020-10-02
Accepted
2020-10-02 17:19:12
Documents
14
Period of Report
2020-10-02
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2031140d2_8k.htm   iXBRL 8-K 28711
2 EXHIBIT 5.1 tm2031140d2_ex5-1.htm EX-5.1 13397
6 GRAPHIC tm2031140d2_ex5-1img001.jpg GRAPHIC 20602
  Complete submission text file 0001104659-20-111774.txt   253914

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA axgt-20201002.xsd EX-101.SCH 3239
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE axgt-20201002_lab.xml EX-101.LAB 34591
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE axgt-20201002_pre.xml EX-101.PRE 22708
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2031140d2_8k_htm.xml XML 3818
Mailing Address 11 TIMES SQUARE 33RD FLOOR NEW YORK NY 10036
Business Address 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FLOOR LONDON X0 SW1Y 4LB 44 203 318 9708
Axovant Gene Therapies Ltd. (Filer) CIK: 0001636050 (see all company filings)

IRS No.: 981333697 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-37418 | Film No.: 201221231
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences